Predictive Value

Sep 20 2011 3:22 PM

Our stable and highly characterized Champions TumorGrafts™ provide the ideal evaluation environment for oncology compounds and data that allow clinical development decisions to be made with confidence, due to their excellent predictive value.

Champions TumorGrafts™ have been shown to correlate with actual patient outcomes based on tumor response, time to tumor progression and survival. This platform is available to researchers developing new oncology drugs to evaluate their drug’s efficacy in a less-costly clinical environment but with a high degree of correlation to the clinical setting.

The predictive power of the Champions TumorGraft™ platform has been demonstrated in numerous clinical applications by Champions’ Personalized Oncology Solutions.

References:

  1. Hidalgo M et al. Activity of gemcitabine in direct patient derived xenografts predicts clinical outcome: validation of an in vivo model for drug development. J Clin Oncol 27:15s, 2009 (suppl; abstr 4528)
  2. Hidalgo M et al. A Pilot Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. Mol Cancer Ther August 2011 10:1311-1316
  3. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006;12:4652-4661.
  4. Champions data on file.